[96a5a0]: / output / allTrials / identified / NCT03979573_identified.json

Download this file

256 lines (256 with data), 10.0 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
{
"info": {
"nct_id": "NCT03979573",
"official_title": "Prospective Phase II Trial Evaluating Multiparametric MRI, Radiomics, MR-guided Biopsy, and Molecular Markers for Active Surveillance of Patients With Low- and Intermediate-Risk Prostate Cancer",
"inclusion_criteria": "* Patients with a Gleason score of 3+3=6 or 3+4=7a and ≤ 33% of positive biopsy cores verified by an at least 12 core systematic prostate biopsy (SB)\n* Organ-confined disease (≤cT2a), note: tumor-positive biopsies in both lobes with non-palpable tumor are rated as cT1c\n* PSA value ≤10 ng/ml\nHealthy volunteers allowed\nMust be MALE",
"exclusion_criteria": "* Gleason score ≥4+3=7b or a Gleason score 3+4=7a with positive biopsy cores >33% of all cores in SB\n* PSA >10 ng/ml\n* Patients not able to give informed consent\n* Contraindication to mp-MRI\n* Contraindication to prostate biopsy",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients with a Gleason score of 3+3=6 or 3+4=7a and ≤ 33% of positive biopsy cores verified by an at least 12 core systematic prostate biopsy (SB)",
"criterions": [
{
"exact_snippets": "Gleason score of 3+3=6 or 3+4=7a",
"criterion": "Gleason score",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"3+3=6",
"3+4=7a"
]
}
]
},
{
"exact_snippets": "≤ 33% of positive biopsy cores",
"criterion": "positive biopsy cores",
"requirements": [
{
"requirement_type": "percentage",
"expected_value": {
"operator": "<=",
"value": 33,
"unit": "%"
}
}
]
},
{
"exact_snippets": "verified by an at least 12 core systematic prostate biopsy (SB)",
"criterion": "systematic prostate biopsy",
"requirements": [
{
"requirement_type": "core count",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "core"
}
}
]
}
]
},
{
"line": "* Organ-confined disease (≤cT2a), note: tumor-positive biopsies in both lobes with non-palpable tumor are rated as cT1c",
"criterions": [
{
"exact_snippets": "Organ-confined disease (≤cT2a)",
"criterion": "disease stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "cT"
}
}
]
},
{
"exact_snippets": "tumor-positive biopsies in both lobes",
"criterion": "tumor-positive biopsies",
"requirements": [
{
"requirement_type": "location",
"expected_value": "both lobes"
}
]
},
{
"exact_snippets": "non-palpable tumor",
"criterion": "tumor palpability",
"requirements": [
{
"requirement_type": "palpability",
"expected_value": false
}
]
}
]
},
{
"line": "* PSA value ≤10 ng/ml",
"criterions": [
{
"exact_snippets": "PSA value ≤10 ng/ml",
"criterion": "PSA value",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 10,
"unit": "ng/ml"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Gleason score ≥4+3=7b or a Gleason score 3+4=7a with positive biopsy cores >33% of all cores in SB",
"criterions": [
{
"exact_snippets": "Gleason score ≥4+3=7b",
"criterion": "Gleason score",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 7,
"unit": "b"
}
}
]
},
{
"exact_snippets": "Gleason score 3+4=7a with positive biopsy cores >33% of all cores",
"criterion": "Gleason score with positive biopsy cores",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": "=",
"value": 7,
"unit": "a"
}
},
{
"requirement_type": "positive biopsy cores",
"expected_value": {
"operator": ">",
"value": 33,
"unit": "% of all cores"
}
}
]
}
]
},
{
"line": "* PSA >10 ng/ml",
"criterions": [
{
"exact_snippets": "PSA >10 ng/ml",
"criterion": "PSA level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "ng/ml"
}
}
]
}
]
},
{
"line": "* Patients not able to give informed consent",
"criterions": [
{
"exact_snippets": "Patients not able to give informed consent",
"criterion": "ability to give informed consent",
"requirements": [
{
"requirement_type": "ability",
"expected_value": false
}
]
}
]
},
{
"line": "* Contraindication to mp-MRI",
"criterions": [
{
"exact_snippets": "Contraindication to mp-MRI",
"criterion": "mp-MRI",
"requirements": [
{
"requirement_type": "contraindication",
"expected_value": true
}
]
}
]
},
{
"line": "* Contraindication to prostate biopsy",
"criterions": [
{
"exact_snippets": "Contraindication to prostate biopsy",
"criterion": "prostate biopsy",
"requirements": [
{
"requirement_type": "contraindication",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}